Your browser doesn't support javascript.
loading
Determinants of Interpatient Variability in Treosulfan Pharmacokinetics in AML Patients Undergoing Autologous Stem Cell Transplantation.
Ayçiçek, Selin G; Akhoundova, Dilara; Bacher, Ulrike; Hayoz, Michael; Aebi, Yolanda; Largiadèr, Carlo R; Pabst, Thomas.
Afiliación
  • Ayçiçek SG; Department of Medical Oncology, Inselspital, University of Bern, CH-3010 Bern, Switzerland.
  • Akhoundova D; Department of Medical Oncology, Inselspital, University of Bern, CH-3010 Bern, Switzerland.
  • Bacher U; Department of Hematology, Inselspital, University of Bern, CH-3010 Bern, Switzerland.
  • Hayoz M; Center of Laboratory Medicine (ZLM), Inselspital, University of Bern, CH-3010 Bern, Switzerland.
  • Aebi Y; Department of Clinical Chemistry, Inselspital, University of Bern, CH-3010 Bern, Switzerland.
  • Largiadèr CR; Center of Laboratory Medicine (ZLM), Inselspital, University of Bern, CH-3010 Bern, Switzerland.
  • Pabst T; Department of Clinical Chemistry, Inselspital, University of Bern, CH-3010 Bern, Switzerland.
Int J Mol Sci ; 25(15)2024 Jul 27.
Article en En | MEDLINE | ID: mdl-39125785
ABSTRACT
Limited data on treosulfan pharmacokinetics in adults, particularly regarding autologous stem cell transplantation (ASCT) in acute myeloid leukemia (AML), is available to date. Furthermore, correlations between treosulfan exposure, toxicity, and clinical outcome remain understudied. In this single-center retrospective study, we analyzed data from 55 AML patients who underwent HDCT with treosulfan (14 g/m2) and melphalan (140 mg/m2 or 200 mg/m2) (TreoMel) between August 2019 and November 2023 at the University Hospital of Bern. We assessed treosulfan pharmacokinetics and correlations with several physiological parameters with potential impact on its interpatient variability. We further analyzed how treosulfan exposure correlates with toxicity and clinical outcomes. Women above 55 years showed higher area under the curve (AUC) levels (median 946 mg*h/L, range 776-1370 mg*h/L), as compared to women under 55 (median 758 mg*h/L, range 459-1214 mg*h/L, p = 0.0487). Additionally, women above 55 showed higher peak levels (median 387 mg/L, range 308-468 mg/L), as compared to men of the same age range (median 326 mg/L, range 264-395 mg/L, p = 0.0159). Treosulfan levels varied significantly with body temperature, liver enzymes, hemoglobin/hematocrit., and treosulfan exposure correlated with diarrhea severity in women over 55 (p = 0.0076). Our study revealed age- and gender-related variability in treosulfan pharmacokinetics, with higher plasma levels observed in female patients above 55. Moreover, our data suggest that treosulfan plasma levels may vary with several physiological parameters and that higher treosulfan exposure may impact toxicity. Our study underlines the need for further research on treosulfan pharmacokinetics, especially in older patients undergoing HDCT in the ASCT setting.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante Autólogo / Busulfano / Leucemia Mieloide Aguda Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Mol Sci Año: 2024 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante Autólogo / Busulfano / Leucemia Mieloide Aguda Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Mol Sci Año: 2024 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Suiza